Alpha 1-Antitrypsin + Placebo
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Alpha 1-Antitrypsin Deficiency
Conditions
Alpha 1-Antitrypsin Deficiency
Trial Timeline
Nov 25, 2019 → Jun 1, 2031
NCT ID
NCT04204252About Alpha 1-Antitrypsin + Placebo
Alpha 1-Antitrypsin + Placebo is a phase 3 stage product being developed by Kamada for Alpha 1-Antitrypsin Deficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04204252. Target conditions include Alpha 1-Antitrypsin Deficiency.
What happened to similar drugs?
2 of 8 similar drugs in Alpha 1-Antitrypsin Deficiency were approved
Approved (2) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04204252 | Phase 3 | Recruiting |
Competing Products
20 competing products in Alpha 1-Antitrypsin Deficiency